Management of refractory lupus nephritis: rationale to consider tacrolimus

Kidney Int. 2022 Jun;101(6):1293. doi: 10.1016/j.kint.2022.03.004.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Lupus Nephritis* / drug therapy
  • Mycophenolic Acid
  • Tacrolimus* / therapeutic use
  • Treatment Outcome

Substances

  • Immunosuppressive Agents
  • Mycophenolic Acid
  • Tacrolimus